

Disclosures

Personal Commercial (0)

No disclosures on record

Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

Personal Organizational or Other Non-Commercial (0)

No disclosures on record

Clinical Trial Enroller (14)

Trial Name	Trial Sponsor	Trial Funding Source
US-based, observational, drug registry of Opsumit® (macitentan) new users in clinical practice	Actelion	
multi-center, open-label, single-arm, Phase 3b study of macitentan in patients with Pulmonary Arterial Hypertension to psychometrically validate the PAH-SYMPACT instrument	Actelion	
Randomised, Double-blind, Chronic Dosing Placebo-controlled, Parallel Group, Multicentre, Phase III Study of 2 Doses of Benralizumab (MEDI-563) in Mod to V Severe COPD	AstraZeneca Pharmaceuticals	
EVALUATION OF FLUID VOLUME IN PATIENTS WITH SEPSIS AND REFRACTORY HYPOTENSION	Cheetah Medical	
Phase III, 52 week, randomized, double-blind, 3-arm parallel group study, comparing fixed dose triple combination FF/UMECH/VI with the fixed dose dual combinations of FF/VI and UMEC/VI	Glaxo Smith Kline	
A multi-center, randomized, placebo-controlled, double-blind, adaptive clinical trial of vitamin C, thiamine and steroids as combination therapy in patients with sepsis	Johns Hopkins	
A Phase 3 Open-label, Multicenter Study to Evaluate the Long-term Safety and Tolerability of LIQ861 (Treprostinil) in Pulmonary Arterial Hypertension WHO Group 1 (PAH) Patients	Liquidia Technologies Inc	
Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of Oral BPS 314d-MR Added-On to Treprostinil, Inhaled (Tyvaso®) in Subjects with PAH	Lung LLC	
Vitamin D to Improve Outcomes by Leveraging Early Treatment: Long-term Brain Outcomes in Vitamin D Deficient Patients (VIOLET-BUD)	National Institutes of Health	
Crystalloids Liberal or Vasopressors Early Resuscitation in Sepsis	National Institutes of Health	
Vitamin D to Improve Outcomes by Leveraging Early Treatment (VIOLET)	National Institutes of Health	
Bardoxolone Methyl in Patients With Connective Tissue Disease-associated Pulmonary Arterial Hypertension - CATALYST	Reata Pharmaceuticals, Inc.	
ADAPT - A Patient Registry of the Real-world Use of Orenitram	United Therapeutics	
Phase III, International, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Event Driven Study to Compare the Time to First Clinical Worsening in Subjects with PAH Receiving UT-15C	United Therapeutics	

Institutional Financial Decision-Making Role (0)

No disclosures on record

Expert Witness Testimony (0)

No disclosures on record

[†] Commercial Funding Source | [‡] Trial Name

Agreement

Certified Education Attestation | Signed on 11/23/2018

URL for full agreement: <http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement>

Confidentiality, Disclosure and Assignment Agreement | Signed on 11/23/2018

URL for full agreement: <http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement>

On-Going Obligation Agreement | Signed on 11/23/2018

ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.